Asset Details
Do you wish to reserve the book?
Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy
Do you wish to request the book?
Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy
2014
Overview
Periodontal disease (POD) may affect rheumatic diseases severity, but there are no data regarding the effect of its treatment on disease activity in SLE patients under immunosuppressive therapy. Forty-nine consecutive SLE patients (SLEDAI ≥ 2) with POD and under corticosteroid and cyclophosphamide pulse therapy (IVCYC) were selected. Periodontal assessment included bleeding gingival index (BGI), probing depth (PD), and probing attachment level (PAL). At entry, POD was defined as BGI > 1 and patients were assigned to groups according to the availability of odontological intervention in TREATED (
n
= 32) and NOT TREATED (
n
= 17). SLEDAI and POD parameters were determined at entry and after 3 months. Age, female gender, and race were alike among TREATED and NOT TREATED (
p
> 0.05). Both groups had also comparable disease duration (10.7 ± 6.8 vs. 11.0 ± 6.6,
p
= 0.83), IVCYC number (5.8 ± 4.8 vs. 4.5 ± 4.8,
p
= 0.17), and SLEDAI (5.9 ± 4.2 vs. 6.3 ± 4.3,
p
= 0.73) as well as POD parameters [BGI (40.8 ± 31.0 vs. 40.7 ± 36.2 %,
p
= 0.89), PD (1.7 ± 1.8 vs. 1.5 ± 0.60 mm,
p
= 0.80), and PAL (2.5 ± 1.9 vs. 1.9 ± 1.1 mm,
p
= 0.18)]. At the end of the study, TREATED group had a significant improvement in SLEDAI (5.9 ± 4.2 vs. 3.4 ± 3.3,
p
= 0.04) with a paralleled reduction in BGI (40.8 ± 31.0 vs. 15.2 ± 17.2 %,
p
< 0.01), PD (1.7 ± 1.8 vs. 1.1 ± 0.3 mm,
p
< 0.01), and PAL (2.5 ± 1.9 vs. 1.7 ± 0.9 mm,
p
< 0.01). In contrast, SLEDAI (6.3 ± 4.3 vs. 6.0 ± 5.5,
p
= 0.40) and POD parameters [BGI (
p
= 0.33), PD (
p
= 0.91), and PAL (
p
= 0.39)] remained largely unchanged in NOT TREATED group. Periodontal disease treatment seems to have a beneficial effect in controlling disease activity in SLE patients under immunosuppressive therapy. Therefore, management of this modifiable risk factor is recommended.
Publisher
Springer London,Springer Nature B.V
